Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A

被引:91
作者
Shire, D
Calandra, B
Delpech, M
Dumont, X
Kaghad, M
LeFur, G
Caput, D
Ferrara, P
机构
[1] Sanofi Recherche, Centre de Labège, 31676 Labège Cédex
关键词
D O I
10.1074/jbc.271.12.6941
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The antagonist SR 141716A has a high specificity for the central CB1 cannabinoid receptor and negligeable affinity for the peripheral CB2 receptor, making it an excellent tool for probing receptor structure-activity relationships. From binding experiments with mutated CB1 and with chimeric CB1/CB2 receptors we have begun to identify the domains of CB1 implicated in the recognition of SR 141716A, Receptors were transiently expressed in COS-3 cells, and their binding characteristics were studied with SR 141716A and with CP 55,940, an agonist recognized equally well by the two receptors. The region delineated by the fourth and fifth transmembrane helices of CB1 proved to be crucial for high affinity binding of SR 141716A. The CB1 and CB2 second extracellular loops, e2, were exchanged, modifications that had no effect on SR 141716A binding in the CB1 variant but that eliminated CP 55,940 binding in both mutants, The replacement of the conserved cysteine residues in e2 of CB2 by serine also eliminated CP 55,940 binding, but replacement of those in CB1 resulted in the sequestration of the mutated receptors in the cell cytoplasm, The e2 domain thus plays some role in CP 55,940 binding but none in SR 141716A recognition, binding of the latter clearly implicating residues in the adjoining transmembrane helices.
引用
收藏
页码:6941 / 6946
页数:6
相关论文
共 50 条
  • [31] Δ9-Tetrahydrocannabinol and Synthetic Cannabinoids Prevent Emesis Produced by the Cannabinoid CB1 Receptor Antagonist/Inverse Agonist SR 141716A
    Nissar A Darmani
    Neuropsychopharmacology, 2001, 24 : 198 - 203
  • [32] SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset
    Simiand, J
    Keane, M
    Keane, PE
    Soubrié, P
    BEHAVIOURAL PHARMACOLOGY, 1998, 9 (02): : 179 - 181
  • [33] Functional inverse agonism of SR141716A on rat and human central cannabinoid CB1 receptor
    Valdizan, E. M.
    Mato, S.
    Pazos, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2001, 15 : 72 - 72
  • [34] The inverse cannabinoid CB1 receptor agonist SR 141716A decreases D-amphetamine-induced behaviours in monkeys
    Madsen, MV
    Peacock, LP
    Werge, T
    Andersen, MB
    BEHAVIOURAL PHARMACOLOGY, 2003, 14 : S42 - S42
  • [35] Probing the Interaction of SR141716A with the CB1 Receptor
    Shim, Joong-Youn
    Bertalovitz, Alexander C.
    Kendall, Debra A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (46) : 38741 - 38754
  • [36] Effects of the cannabinoid CB1 receptor antagonist, SR141716A, after Δ9-tetrahydrocannabinol withdrawal
    Beardsley, PM
    Martin, BR
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 387 (01) : 47 - 53
  • [37] Cannabinoid CB1 antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats
    Fattore, L
    Spano, S
    Cossu, G
    Deiana, S
    Fadda, P
    Fratta, W
    NEUROPHARMACOLOGY, 2005, 48 (08) : 1097 - 1104
  • [38] SR141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine
    Masserano, JM
    Karoum, F
    Wyatt, RJ
    BEHAVIOURAL PHARMACOLOGY, 1999, 10 (04): : 429 - 432
  • [39] Inverse agonist effects of the cannabinoid CB1 receptor antagonist SR141716A in rat brain.
    Sim-Selley, LJ
    Brunk, LK
    Selley, DE
    FASEB JOURNAL, 2000, 14 (08) : A1447 - A1447
  • [40] The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus
    Tzavara, ET
    Perry, KW
    Rodriguez, DE
    Bymaster, FP
    Nomikos, GG
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 426 (03) : R3 - R4